Dexamethasone (DEX)-mediated inhibition of druginduced, but not CD95 ligand-induced, apoptosis in malignant glioma cells correlates with wild-type p53 status. Here, we examined mechanisms underlying DEXmediated protection from apoptosis. DEX did not induce p53 expression in two p53 wild-type cell lines (U87MG, LN-229) and did not alter drug-induced p53 accumulation. human colon carcinoma cells. Paradoxically, while only p21 +/+ and p21 +/7 mouse embryonic ®broblasts showed enhance p21 WAF1/CIP1 levels after exposure to DEX, only p21 7/7 ®broblasts were protected from drug toxicity by DEX. The present study links DEX-mediated protection from cancer chemotherapy to a p53-independent pathway of regulating p21 WAF1/CIP1 expression in glioma cells but this eect appears to cell type-speci®c.
Dexamethasone (DEX)-mediated inhibition of druginduced, but not CD95 ligand-induced, apoptosis in malignant glioma cells correlates with wild-type p53 status. Here, we examined mechanisms underlying DEXmediated protection from apoptosis. DEX did not induce p53 expression in two p53 wild-type cell lines (U87MG, LN-229) and did not alter drug-induced p53 accumulation. Forced expression of temperature-sensitive p53val 135 in mutant conformation failed to prevent accumulation of endogenous wild-type p53 but acted in a transdominant negative manner to inhibit p53-mediated, camptothecininduced p21 WAF1/CIP1 expression. p53val
135
-transfected cells retained responsiveness to DEX at restrictive temperature, suggesting that p53 activity is not required for cytoprotection. Forced expression of wild-type p53val human colon carcinoma cells. Paradoxically, while only p21 +/+ and p21 +/7 mouse embryonic ®broblasts showed enhance p21 WAF1/CIP1 levels after exposure to DEX, only p21 7/7 ®broblasts were protected from drug toxicity by DEX. The present study links DEX-mediated protection from cancer chemotherapy to a p53-independent pathwayIntroduction Steroids such as dexamethasone (DEX) are classical inducers of apoptotic cell death in lymphoid cells (Wyllie, 1980; Cohen, 1991; Golstein et al., 1991) . However, most non-lymphoid cells are resistant to DEX-induced apoptosis. DEX has even been shown to have antiapoptotic properties, e.g., in the context of CD95-mediated apoptosis of human malignant glioma cells (Weller et al., 1994b) . Human glioma patients are treated with steroid medications for the control of cerebral edema and prevention of side eects from radiotherapy. However, steroid use should be limited during adjuvant chemotherapy of malignant gliomas because steroids may reduce drug delivery to the tumor upon systemic application due to its eects on cerebral and speci®cally tumor blood ow and on blood-tumoral barrier functions. Moreover, we have recently reported that preexposure of human malignant glioma cell lines to DEX attenuates the cytotoxic and antiproliferative eects of several cytotoxic drugs with distinct modes of action (Weller et al., 1997a) . In a comparative study of various glioma cells lines, wild-type p53 status predicted a good cytoprotective response to DEX whereas cell lines mutant or deleted for p53 bene®ted much less from DEX-mediated cytoprotection. DEXinduced growth arrest was not required for protection. In the present study, we sought to identify the molecular mechanisms underlying the association between p53 status and DEX-mediated protection from chemotherapy.
Results

DEX does not induce p53 protein expression and does not alter drug-induced p53 accumulation in malignant glioma cells expressing wild-type p53
Previous work from our laboratory had shown that glioma cell lines with wild-type p53 status (LN-229, U87MG) were protected from drug cytotoxicity by DEX much better than glioma cells lacking wild-type p53 activity. LN-18 was the single cell line lacking wild-type p53 that responded to DEX-mediated cytoprotection (Weller et al., 1997a) (Figure 1a and b). Here, we ®rst asked whether DEX protected from drug toxicity upstream or downstream of drug-induced activation of p53 in glioma cells with wild-type p53 status. Figure 1c shows that cytoprotective concentrations of DEX did not modulate constitutive p53 expression, when administered alone, and had no signi®cant eect on p53 accumulation in LN-229 cells exposed to teniposide (VM26), vincristine (VCR) or doxorubicine. As predicted, T98G cells which harbour mutant p53 exhibited no change in the expression of p53 after drug exposure (data not shown).
A transdominant negative p53 mutant fails to abrogate the cytoprotective eects of DEX in LN-229 cells
To examine whether wild-type p53 is strictly required for DEX-mediated protection from chemotherapy, we took advantage of the murine temperature-sensitive p53val 135 mutant which is a transdominant negative mutant at restrictive temperature (Ewen et al., 1995; Harvey et al., 1995) . Pooled p53 transfectants were generated as described (Trepel et al., 1998) . First, we asked whether p53val 135 expressed in mutant conformation modulates drug-induced accumulation of endogenous wild-type p53 in LN-229 cells. This was not the case. Exposure to camptothecin, a strong stimulus for p53 accumulation in LN-229 cells (Weller et al., 1997c) , resulted in a concentration-dependent increase in endogenous p53 levels in hygro control cells as well as in p53val 135 -transfected cells ( Figure 2a ). As expected, the grafted murine p53 protein was only detected in transfected but not in hygro control cells; further, consistent with its ectopic expression from the LTR promoter of the plasmid, p53val
135 levels were unchanged after exposure to camptothecin (Figure 2b ). However, p53val
135 suppressed wild-type p53-dependent accumulation of the major p53 response gene product, p21 WAF1/CIP1 , after exposure to camptothecin (Figure 2c) (Trepel et al., 1998) . Here, we focus on the modulatory eects of DEX on drug sensitivity depending on the p53 background. LN-18 or LN-229 cells expressing hygro or p53val 135 were either not pretreated or pretreated with DEX for 24 h and subsequently exposed to VM26, vincristine or BCNU, in the absence or presence of DEX for 72 h at 38.58C. Figure 3 summarizes the data for VM26 and vincristine. In the present study, using 72 h continuous drug exposure, mutant p53 had little eect on the sensitivity of LN-18 cells to VM26, vincristine, or BCNU. In LN-229 cells, mutant p53 conferred minor protection from VM26 and vincristine but enhanced the eects of BCNU. Wild-type p53, which induced growth arrest, rendered both cell lines relatively more resistant to vincristine, and LN-18 cells to VM26, too. VM26 toxicity in LN-229 cells, and BCNU toxicity in both cell lines, were unaected by wild-type p53 expression. Importantly, transdominant negative inhibition of p53 at 38.58C had no eect on DEX-dependent protection from chemotherapy in LN-229 cells. Thus, wild-type p53 is not required for DEX-mediated cytoprotection in these cells. Further, when the same experiment was carried out at 32.58C, to allow for accumulation of ectopic accumulation of p53val 135 in wild-type conformation, DEX was no more cytoprotective. Since activation of wild-type p53 at 32.58C induces partial drug resistance on its own (Trepel et al., 1998) , we concluded that there might be redundance of the cytoprotective eects of DEX and wild-type p53. A similar observation was made in LN-18 cells engineered to express p53val 135 ( Figure 3 , upper right). Of the cell lines which lack wild-type (7) or pretreated with DEX (100 nM) (+) for 24 h and then exposed to VM26 (10 mM), vincristine (VCR, 2 mM) or doxorubicine (DXR, 0.5 mM) in the absence (7) or presence (+) of DEX for 24 h. Soluble protein lysates were harvested and immunoblot analysis for p53 was performed as described. The size markers in the outer left lane correspond to 101, 83, 50.6 and 35.5 kDa p53, these cells show the strongest cytoprotective response to DEX (Figure 1 ). Yet, after activation of ectopic p53 in wild-type conformation, DEX was no more protective in LN-18 cells either.
Cytoprotection from chemotherapy aorded by DEX is associated with p21
WAF1/CIP1 accumulation Induction of p21 WAF1/CIP1 expression is thought to be chie¯y responsible for p53-mediated growth arrest and is prominent after changing the conformation of p53val 135 from mutant to wild-type in LN-18 and LN-229 glioma cells (Trepel et al., 1998) . We hypothesized that induction of p21 WAF1/CIP1 might be responsible for the apparent redundance of cytoprotection mediated by p53val 135 in wild-type conformation and DEX. Therefore, we asked whether the levels of p21 WAF1/CIP1 were modulated by DEX. There was indeed a mild accumulation of p21 WAF1/CIP1 in DEX-treated LN-229 and U87MG cells (Figure 4a ). However, there was a much stronger response to camptothecin, as expected for cell lines harbouring wild-type p53. Interestingly, there was also a minor increase in p21 WAF1/CIP1 levels in LN-18 cells after exposure to DEX but no response in LN-308 or T98G cells. Among the p53 mutant cell lines, T98G also showed a consistent increase p21 WAF1/CIP1 protein in response to camptothecin.
Next we examined whether the increase in p21 WAF1/ CIP1 protein levels induced by DEX was associated with increased p21 WAF1/CIP1 gene transcription or resulted from altered posttranslational regulatory mechanisms. Figure 4b shows that there was no major increase in p21 WAF1/CIP1 mRNA after exposure to cytoprotective concentrations of DEX for 24 h, including cell lines LN-229, U87MG and LN-18 which showed enhanced p21 WAF1/CIP1 protein after DEX exposure. In contrast, there was strong induction of p21 WAF1/CIP1 mRNA expression after exposure to camptothecin in cell lines with wild-type p53 status (U87MG, LN-229) but not in the other cell lines. The results shown in Figure 3 had indicated that ectopic expression of the transdominant negative p53val 135 mutant did not aect DEX-mediated cytoprotection. We then examined whether DEX could still induce p21 WAF1/CIP1 accumulation in p53val 135 -transfected LN-229. Since this was the case (data not shown), DEX-induced p21 WAF1/CIP1 accumulation in responsive cell lines is p53-independent.
DEX-mediated protection from chemotherapy does not correlate with protection from CD95 ligand-induced apoptosis
We had previously observed that DEX not only attenuated cytotoxic eects of cancer chemotherapy drugs (Weller et al., 1997a) but also apoptosis of human malignant glioma cells exposed to agonistic CD95 antibodies (Weller et al., 1994b) . Here, we extend these observations to the natural CD95 ligand. In contrast to DEX-mediated inhibition of drug toxicity (Figure 1 ), DEX-mediated inhibition of CD95 ligand-induced apoptosis was detected in all cell lines, irrespective of p53 status, and was even rather prominent in cell lines lacking wild-type p53. Figure 5 shows a typical experiment. The protective eect of DEX is attenuated in most cell lines when the cells are exposed to CD95 ligand in the presence of an inhibitor of protein synthesis, cycloheximide, a potent enhancer of CD95 antibody-induced apoptosis (Weller et al., 1994b) . -transfected (right) cells were untreated or exposed for 24 h to camptothecin (CPT) at 0.125, 0.5 or 2 mM at 38.58C. Soluble protein lysates were prepared and subjected to SDS ± PAGE. The samples were examined by immunoblot analysis for endogenous p53 using pAb1801 (a) or the grafted p53val 135 protein using pAb240 (b) or for p21 WAF1/CIP1 (c)
DEX-mediated protection from chemotherapy does not involve changes in glutathione levels
Inhibition of drug-induced cytotoxicity in glioma cells by DEX has recently been linked to DEX-induced increases in glutathione synthesis (Wol et al., 1996) . This mechanism does not appear to be operative in our experimental paradigm since there was no change in glutathione levels after exposure to cytoprotective concentrations of DEX for 24 h in either cell line ( Figure 6 ).
DEX-mediated p21
WAF1/CIP1 accumulation and cytoprotection are cell type-speci®c
The ®nal series of experiments was performed to examine whether the association of DEX-mediated p21 WAF1/CIP1 accumulation and cytoprotection was (Figure 8b) , precluding a ®rm conclusion on the association of p21 WAF1/CIP1 accumulation and cytoprotection in these cells. p21 7/7 colon carcinoma cells were more sensitive to VM26 and VCR, but not BCNU, than p21 +/+ or p21 +/7 cells, consistent with a role for p21 WAF1/CIP1 in protection from chemotherapy (Fan et al., 1997) . Finally, mouse embryonic ®broblasts retaining at least one p21 WAF1/CIP1 allele show p21 WAF1/CIP1 accumulation after DEX exposure (Figure 7c ) but do not respond to Figure 4 DEX promotes p21 WAF1/CIP1 protein accumulation but does not increase p21 WAF1/CIP1 mRNA levels in human malignant glioma cell lines expressing wild-type p53 activity. (a) LN-229, U87MG, LN-18, LN-308 or T98G were untreated or treated with DEX (100 nM) or camptothecin (CPT) (2 mM) for 24 h. p21 WAF1/CIP1 levels were assessed by immunoblot analysis as described. (b) The cells were untreated (open bars) or exposed to DEX (100 nM, hatched bars; 10 mM, grey bars) or camptothecin (2 mM, black bars) for 24 h. Northern blot analysis was performed as described and p21 WAF1/CIP1 mRNA expression quanti®ed by phosphoimager and normalized against 28S ribosomal RNA DEX with enhanced survival after drug exposure (Figure 8c ). In contrast, ®broblasts devoid of p21 WAF1/ CIP1 bene®t from DEX in terms of protection from the DNA damaging agents, BCNU, VM26 and doxorubicin, as well as from the microtubule-interacting drugs VCR and taxol, and also from staurosporine toxicity. In contrast to the colon carcinoma cells, the ®broblasts lacking p21 WAF1/CIP1 were not signi®cantly more chemosensitive than the parental cells. Taken together, these data indicate that the link between p21 WAF1/CIP1 accumulation and cytoprotection as observed in the glioma cell lines is probably cell typespeci®c (or epiphenomenal).
DEX does not modulate the expression of members of the BCL-2 family proteins
Previous work from our laboratory has shown that bcl-2 gene transfer confers resistance to chemotherapeutic drugs (Weller et al., 1995a) whereas bax gene transfer fails to sensitize malignant glioma cells (Naumann and . However, DEX has previously been shown not to alter BCL-2 or BAX protein levels (Weller et al., 1997a) . To elucidate whether DEX modulates the expression of other BCL-2 family proteins in malignant glioma cells, as a pathway for DEX-mediated cytoprotection , we examined protein levels of pro-as well as of antiapoptotic members of the BCL-2 family. Since there were neither changes in BCL-X L/S or MCL-1, nor in BAK protein levels, detectable (data not shown), this mechanism does not appear to be involved in DEX-mediated cytoprotection in malignant glioma cells.
Discussion
The present study sought to identify the molecular mechanisms underlying DEX-mediated protection from apoptotic cell death in human malignant glioma cells. Although steroids are potent inducers of lymphocyte apoptosis (Wyllie et al., 1980; Cohen, 1991; Golstein et al., 1991) , antiapoptotic actions of steroids may not be limited to glioma cells (Weller et al., 1994b) but have also been noted in neutrophils (Cox 1995; Cox and Austin, 1997) . DEX-mediated increases in intracellular glutathione (Wol et al., 1996) were excluded as the responsible mechanism in this study (Figure 6 ). More than one mechanism may be involved in prevention of apoptosis by DEX in glioma cells since, among the cell lines studied, DEX-induced protection from cytotoxic drugs (Figure 1 ) did not correlate with DEX-induced inhibition of CD95 ligand-induced apoptosis (Figure , c) were untreated or exposed to DEX (100 nM) for 24 h. p21 WAF1/ CIP1 expression was assessed by immunoblot analysis as described in Materials and methods 5). Protection from cytotoxic drugs was prominent in wild-type p53 cell lines (LN-229, U87MG) but also observed in one p53 mutant cell line (LN-18) . A minor induction of p21 WAF1/CIP1 expression was the most reliable predictor of a cytoprotective response to DEX when subsequently challenged with cytotoxic drugs (Figure 1b and 4) . We have previously hypothesized that the strong induction of p21 WAF1/CIP1 by temperature-sensitive p53val 135 at permissive temperature prevents a p53-mediated sensitization to chemotherapy in glioma cells (Trepel et al., 1998) . Although p21 WAF1/CIP1 has been advocated as a target gene for gene transfer-based cancer therapy because of its growth inhibitory eects (Eastham et al., 1995; Kondo et al., 1996; Chen et al., 1996) , several lines of evidence have recently linked p21 WAF1/CIP1 to prevention of apoptosis (Waldman et al., 1996; Gorospe et al., 1996 Gorospe et al., , 1997 .
Our study also provides evidence for more than one pathway for the regulation of p21 WAF1/CIP1 expression in glioma cells. Basal expression of p21 WAF1/CIP1 , e.g., in LN-229 is likely to depend on constitutive p53 activity since it was suppressed by dominant negative p53val 135 (Figure 2 ). In contrast, the DEX-induced increase in p21 WAF1/CIP1 levels occurred in the absence of endogenous p53 accumulation (Figure 1c) and was unaected by ectopic expression of p53val 135 at restrictive temperature. In MCF-7 breast cancer cells, increased p21 WAF1/CIP1 protein levels after exposure to retinoids was attributed to enhanced stability of p21 WAF1/CIP1 mRNA (Li et al., 1996) . Here, p21 WAF1/CIP1 protein levels increased after DEX stimulation in the absence of changes in p21 WAF1/CIP1 mRNA expression, suggesting that mRNA is translated more eciently or that the protein is stabilized.
Eorts to delineate a universal role for p21
induction in DEX-mediated cytoprotection by comparing otherwise isogenic human colon carcinoma cells or mouse embryonic ®broblasts with deletion of both p21 WAF1/CIP1 alleles failed (Figures 7 and 8) . Colon carcinoma cells were not informative because there was neither DEX-mediated p21 WAF1/CIP1 accumulation nor DEX-mediated cytoprotection. Contrary to the expectations, the murine embryonic ®broblasts retaining p21 WAF1/CIP1 showed p21 WAF1/CIP1 accumulation in response to DEX whereas only the p21 7/7 cells showed DEX-mediated protection from chemotherapeutic drugs. Finally, a cytoprotective eect appeared even to be speci®c for neoplastic glial cells since neither p21 WAF1/ CIP1 accumulation nor cytoprotection in response to DEX were observed in untransformed rat astrocytes (Figures  7a and 8a) . Further, while this work was being reviewed, Chang et al. (1997) reported that DEX mediated cytoprotection of gastric carcinoma cells via induction of BCL-X expression, an eect of DEX that was excluded in our study (data not shown).
The implications of DEX-mediated cytoprotection for adjuvant chemotherapy of malignant glioma are obvious and have been discussed elsewhere (Weller et al., 1997a) . However, steroids are also given to patients with other neoplasms, e.g., during radiotherapy. While we expect that lymphoid and hematopoietic cancer cells will behave dierently and not like glioma cells, DEXmediated inhibition of cancer drug cytotoxicity may ) (c) were exposed to VCR (astrocytes and colon carcinoma cells, 1 mM; MEF, 0.5 mM), VM26 (astrocytes, 3.3 mM; colon carcinoma cells, 1 mM; MEF, 2 mM), BCNU (1 mM), doxorubicine (ADM, 1 mM), taxol (3 mM) or staurosporine (30 nM) for 72 h in the absence of DEX (open bars) or with a 24 h pretreatment and 72 h cotreatment with DEX (100 nM) (black bars). Survival was assessed by crystal violet staining. Data are expressed mean percentages of survival and s.e.m. (*P50.05, t-test) well play a previously unrecognized role in the chemotherapy of other solid tumors. This may especially be true for patients treated concurrently with chemotherapy and radiotherapy for cerebral metastasis since such patients are always treated with steroids for the prevention of neurotoxicity from cerebral irradiation.
Materials and methods
Materials
Dexamethasone, vincristine and cycloheximide were obtained from Sigma (St Louis, MO), VM26 and BCNU from Sandoz (Basel, Switzerland) and Bristol (Syracuse, NY), respectively. DMEM and fetal bovine serum were obtained from GIBCO Life Technologies (Eggenstein, Germany).
[a 32P ]dATP was purchased from Amersham (Braunschweig, Germany). CD95 ligand was obtained from CD95 ligand cDNA-transfected Neuro2A neuroblastoma cells and used for cytotoxicity assays as described (Roth et al., 1997) .
Cell lines and cell culture
Five established human malignant glioma cell lines, U87MG, T98G, LN-18, LN-229 and LN-308, were kindly provided by Dr N de Tribolet (Lausanne, Switzerland). The cells were maintained in DMEM containing 10% fetal calf serum (FCS), 1% glutamine, and antibiotics as described (Weller et al., 1994b (Weller et al., , 1995a . Cytotoxicity assays were performed in serum-free DMEM. Survival was assessed by crystal violet staining. The p53 status of these cells is as follows: LN-229 is heterozygous with transcriptional activity, U87MG is wild-type for p53. LN-18 and T98G cells express mutant p53 protein. LN-308 cells have a p53 deletion that results in the lack of p53 protein expression (Van Meir et al., 1994; Weller et al., 1997b) . Newborn rat astrocytes were prepared as previously described (Weller et al., 1994a) . p21 +/+ (HCT116), p21 +/7 (HCT116 #80) and p21 7/7 (HCT116 #80S4) human colon carcinoma cells were kindly provided by B Vogelstein (Waldman et al., 1995 (Waldman et al., , 1996 . p21 +/+ , p21
and p21 7/7 mouse embryonic ®broblasts were kindly provided by K Mercer and T Jacks (Brugarolas et al., 1995) .
Transfections
Glioma cells stably expressing p53val
135 were obtained by electroporation (Biorad Gene Pulser, 250 V, 950 mF) using the p53val 135 hygro vector (Ryan et al., 1994) , kindly provided by MF Clarke (Pittsburgh, PA). Control cells were transfected with a p65 hygro control plasmid. Cells were selected for 8 weeks in hygromycin (200 mg/ml) and transgene expression assessed by immunoblot analysis using p53 pAb240 (Calbiochem, Bad Soden, Germany).
Northern blot analysis
Total RNA was extracted using the RNA puri®cation system (RNeasy, Qiagen, Hilden, Germany) according to the manufacturer's instructions. For Northern analysis, 10 mg of total RNA were denatured and electrophoresed on 1.2% agarose gels. After electrophoresis RNA was transferred to nylon membranes (Hybond N, Amersham). The ®lters were hybridized with 32 P labelled p21 WAF1/CIP1 cDNA probes as described (Chomczynski, 1992) . After hybridization, the ®lters were washed three times with 0.1% SSC/0.1% SDS for 30 min at 658C and bound radioactivity was quanti®ed on a phospho-imager using the TINA program (Fushi BasReader 1500, Raytest, Staubenhardt, Germany). p21 WAF1/CIP1 mRNA was normalized against 28S rRNA detected by methylen blue stain (Herrin and Schmidt, 1988) . The human p21 WAF1/CIP1 cDNA was kindly provided by Dr B Vogelstein (Baltimore, MD).
Immunoblot analysis
Exponentially growing cells were washed twice with PBS and lysed in a solution containing 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 0.5% NP-40 and 1 mM phenylmethylsulfonyl¯uoride (PMSF), 1 mM leupeptin and 1 mM aprotinin for 15 min on ice, and then centrifuged at 12 000 g at 48C for 15 min. The protein concentration in the supernatant was determined using the Biorad protein assay (Biorad, Hercules, CA) and soluble protein (20 mg) was resolved by sodium dodecylsulfatepolyacrylamide gel electrophoresis (SDS ± PAGE). After electrophoresis, proteins were transferred to nitrocellulose membranes (Biorad, Hercules, CA). The blots were pretreated for 4 h with PBS containing 5% skim milk, 0.05% Tween 20 and then incubated for 16 h with the appropriate antibody: anti-p21 WAF1/CIP1 (clone C19, Santa Cruz Biotechnology, Santa Cruz, CA for human p21 WAF1/ CIP1 ; clone SX118, Pharmingen, Santa Cruz, CA for murine and rat p21 WAF1/CIP1 ), anti-p53 (Calbiochem, Bad Soden, Germany), anti-BCL-2 (clone 100), anti-BCL-X S/L (clone L19), anti-MCL-1 (clone L19) and anti-BAK (clone G25) (Santa Cruz Biotechnology, Santa Cruz, CA). Visualization of protein bands was accomplished using NBT/BCIP or the ECL detection system (Amersham).
Glutathione measurements
Glutathione was assayed as total glutathione (GSX), this is, the sum of the reduced and oxidized forms (GSH + 2 GSSG) and as glutathione disul®de (GSSG) by a modi®ed enzymatic microtiter plate assay. Brie¯y, cells were washed in PBS, lysed in 1% sulfosalicylic acid, centrifuged and GSX content was determined after addition of dithiobisnitrobenzoic acid to aliquots of the supernatant at a ®nal concentration of 10 mM by absorbance changes at 405 nm for 10 min. To determine GSSG levels, reduced glutathione was derivatized with 2.5% vinylpyridine for 60 min prior to kinetic measurement (WuÈ llner et al., 1996) . Protein content was determined using the Lowry method.
